Why Nuvalent Shares Are Surging 45% Today?

Loading...
Loading...
  • Nuvalent Inc NUVL announced the initial data from the Phase 1 dose-escalation portion of its ongoing ARROS-1 Phase 1/2 clinical trial of NVL-520 in advanced ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumors. 
  • Preliminary activity data reported as of the data cut-off date were available from 21 heavily pre-treated response-evaluable NSCLC patients, of which partial responses were observed in 48% (10/21).
  • In patients with ROS1 G2032R mutations, Objective Response Rate (ORR) was 78%.
  • Related: Nuvalent Highlights New Data Exhibiting Expanded Preclinical Activity Of NVL-520 In ROS1-Driven Cancers.
  • Patients with a history of CNS metastases (ORR 73%, 8/11).
  • The most heavily pre-treated of patients receiving two or more prior ROS1 TKIs and one or more prior lines of chemotherapy (ORR 53%, 9/17).
  • In patients previously treated with lorlatinib or repotrectinib, ORR was 50%.
  • As of the preliminary data cut-off date, 76% (16/21) of response-evaluable patients continued on NVL-520 treatment. Enrollment in the Phase 1 portion of the trial is ongoing.
  • Price Action: NUVL shares are up 45.8 at $32.08 on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...